6 "sarcoma" clinical trials found.
-
AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY
CD19-directed autologous CAR T-cell therapy has changed the treatment landscape for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Nonetheless, up to 60 ... -
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
This trial is a Phase II/III evaluation of CC-486 (oral azacitidine) added to R-mini-CHOP. The primary endpoint of the Phase II component is 1-year ... -
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH A NON RANDOMIZED SINGLE ARM US EXTENSION OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
This is a Phase III, open-label, multicenter, randomized controlled trial in patients with R/R FL after receiving at least 1 line of systemic therapy ... -
A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
T cells are an integral part of the immune system that kills cancer cells in the body. T cells have been harvested from peripheral blood ... -
GBM AGILE TRIAL
Glioblastoma adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies ... -
M20-638: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL TRIAL OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO RITUXIMAB AND LENALIDOMIDE (R2) ALONE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
This is a trial testing a new medicine called epcoritamab, when used with other medicines called rituximab and lenalidomide (together called "R2"), to see if ...